Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

A bidentate Polycomb Repressive-Deubiquitinase complex is required for efficient activity on nucleosomes.

Foglizzo M, Middleton AJ, Burgess AE, Crowther JM, Dobson RCJ, Murphy JM, Day CL, Mace PD.

Nat Commun. 2018 Sep 26;9(1):3932. doi: 10.1038/s41467-018-06186-1.

2.

Substrate binding allosterically relieves autoinhibition of the pseudokinase TRIB1.

Jamieson SA, Ruan Z, Burgess AE, Curry JR, McMillan HD, Brewster JL, Dunbier AK, Axtman AD, Kannan N, Mace PD.

Sci Signal. 2018 Sep 25;11(549). pii: eaau0597. doi: 10.1126/scisignal.aau0597.

3.

The activity of TRAF RING homo- and heterodimers is regulated by zinc finger 1.

Middleton AJ, Budhidarmo R, Das A, Zhu J, Foglizzo M, Mace PD, Day CL.

Nat Commun. 2017 Nov 27;8(1):1788. doi: 10.1038/s41467-017-01665-3.

4.

Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding.

Feltham RL, Moulin M, Vince JE, Mace PD, Wong WW, Anderton H, Day CL, Vaux DL, Silke J.

J Biol Chem. 2017 Aug 25;292(34):14310. doi: 10.1074/jbc.A109.087635. No abstract available.

5.

Live and let die: insights into pseudoenzyme mechanisms from structure.

Murphy JM, Mace PD, Eyers PA.

Curr Opin Struct Biol. 2017 Dec;47:95-104. doi: 10.1016/j.sbi.2017.07.004. Epub 2017 Aug 5. Review.

PMID:
28787627
6.

Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors.

Lechtenberg BC, Mace PD, Sessions EH, Williamson R, Stalder R, Wallez Y, Roth GP, Riedl SJ, Pasquale EB.

ACS Med Chem Lett. 2017 Jun 12;8(7):726-731. doi: 10.1021/acsmedchemlett.7b00127. eCollection 2017 Jul 13.

7.

Structural basis of autoregulatory scaffolding by apoptosis signal-regulating kinase 1.

Weijman JF, Kumar A, Jamieson SA, King CM, Caradoc-Davies TT, Ledgerwood EC, Murphy JM, Mace PD.

Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2096-E2105. doi: 10.1073/pnas.1620813114. Epub 2017 Feb 27.

8.

When Worlds Collide-Mechanisms at the Interface between Phosphorylation and Ubiquitination.

Filipčík P, Curry JR, Mace PD.

J Mol Biol. 2017 Apr 21;429(8):1097-1113. doi: 10.1016/j.jmb.2017.02.011. Epub 2017 Feb 21. Review.

PMID:
28235544
9.

Structural Studies of ERK2 Protein Complexes.

Weijman JF, Riedl SJ, Mace PD.

Methods Mol Biol. 2017;1487:53-63.

PMID:
27924558
10.

Noncovalent Ubiquitin Interactions Regulate the Catalytic Activity of Ubiquitin Writers.

Wright JD, Mace PD, Day CL.

Trends Biochem Sci. 2016 Nov;41(11):924-937. doi: 10.1016/j.tibs.2016.08.003. Epub 2016 Sep 7. Review.

PMID:
27614784
11.

Smoking and Adverse Outcomes in Fibromuscular Dysplasia: U.S. Registry Report.

O'Connor S, Gornik HL, Froehlich JB, Gu X, Gray BH, Mace PD, Sharma A, Olin JW, Kim ES.

J Am Coll Cardiol. 2016 Apr 12;67(14):1750-1. doi: 10.1016/j.jacc.2016.01.058. No abstract available.

12.

Structure of a HOIP/E2~ubiquitin complex reveals RBR E3 ligase mechanism and regulation.

Lechtenberg BC, Rajput A, Sanishvili R, Dobaczewska MK, Ware CF, Mace PD, Riedl SJ.

Nature. 2016 Jan 28;529(7587):546-50. doi: 10.1038/nature16511. Epub 2016 Jan 20.

13.

Secondary ubiquitin-RING docking enhances Arkadia and Ark2C E3 ligase activity.

Wright JD, Mace PD, Day CL.

Nat Struct Mol Biol. 2016 Jan;23(1):45-52. doi: 10.1038/nsmb.3142. Epub 2015 Dec 14.

PMID:
26656854
14.

Molecular Mechanism of CCAAT-Enhancer Binding Protein Recruitment by the TRIB1 Pseudokinase.

Murphy JM, Nakatani Y, Jamieson SA, Dai W, Lucet IS, Mace PD.

Structure. 2015 Nov 3;23(11):2111-21. doi: 10.1016/j.str.2015.08.017. Epub 2015 Oct 9.

15.

Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor.

Lamberto I, Lechtenberg BC, Olson EJ, Mace PD, Dawson PE, Riedl SJ, Pasquale EB.

ACS Chem Biol. 2014 Dec 19;9(12):2787-95. doi: 10.1021/cb500677x. Epub 2014 Oct 14.

16.

Structural mechanisms in NLR inflammasome signaling.

Lechtenberg BC, Mace PD, Riedl SJ.

Curr Opin Struct Biol. 2014 Dec;29:17-25. doi: 10.1016/j.sbi.2014.08.011. Epub 2014 Sep 15. Review.

17.

Caspase enzymology and activation mechanisms.

Mace PD, Riedl SJ, Salvesen GS.

Methods Enzymol. 2014;544:161-78. doi: 10.1016/B978-0-12-417158-9.00007-8.

PMID:
24974290
18.

Clinical manifestations of fibromuscular dysplasia vary by patient sex: a report of the United States registry for fibromuscular dysplasia.

Kim ESH, Olin JW, Froehlich JB, Gu X, Bacharach JM, Gray BH, Jaff MR, Katzen BT, Kline-Rogers E, Mace PD, Matsumoto AH, McBane RD, White CJ, Gornik HL.

J Am Coll Cardiol. 2013 Nov 19;62(21):2026-2028. doi: 10.1016/j.jacc.2013.07.038. Epub 2013 Aug 14. No abstract available.

19.

Design, synthesis and evaluation of inhibitor of apoptosis protein (IAP) antagonists that are highly selective for the BIR2 domain of XIAP.

Ardecky RJ, Welsh K, Finlay D, Lee PS, González-López M, Ganji SR, Ravanan P, Mace PD, Riedl SJ, Vuori K, Reed JC, Cosford ND.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4253-7. doi: 10.1016/j.bmcl.2013.04.096. Epub 2013 May 14.

20.

Structure of ERK2 bound to PEA-15 reveals a mechanism for rapid release of activated MAPK.

Mace PD, Wallez Y, Egger MF, Dobaczewska MK, Robinson H, Pasquale EB, Riedl SJ.

Nat Commun. 2013;4:1681. doi: 10.1038/ncomms2687.

21.

Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP.

Vamos M, Welsh K, Finlay D, Lee PS, Mace PD, Snipas SJ, Gonzalez ML, Ganji SR, Ardecky RJ, Riedl SJ, Salvesen GS, Vuori K, Reed JC, Cosford ND.

ACS Chem Biol. 2013 Apr 19;8(4):725-32. doi: 10.1021/cb3005512. Epub 2013 Feb 5.

22.

NSP-CAS Protein Complexes: Emerging Signaling Modules in Cancer.

Wallez Y, Mace PD, Pasquale EB, Riedl SJ.

Genes Cancer. 2012 May;3(5-6):382-93. doi: 10.1177/1947601912460050.

23.

The CARD plays a critical role in ASC foci formation and inflammasome signalling.

Proell M, Gerlic M, Mace PD, Reed JC, Riedl SJ.

Biochem J. 2013 Feb 1;449(3):613-21. doi: 10.1042/BJ20121198.

24.

NSP-Cas protein structures reveal a promiscuous interaction module in cell signaling.

Mace PD, Wallez Y, Dobaczewska MK, Lee JJ, Robinson H, Pasquale EB, Riedl SJ.

Nat Struct Mol Biol. 2011 Nov 13;18(12):1381-7. doi: 10.1038/nsmb.2152.

25.

Design, synthesis and evaluation of monovalent Smac mimetics that bind to the BIR2 domain of the anti-apoptotic protein XIAP.

González-López M, Welsh K, Finlay D, Ardecky RJ, Ganji SR, Su Y, Yuan H, Teriete P, Mace PD, Riedl SJ, Vuori K, Reed JC, Cosford ND.

Bioorg Med Chem Lett. 2011 Jul 15;21(14):4332-6. doi: 10.1016/j.bmcl.2011.05.049. Epub 2011 May 24.

26.

Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization.

Feltham R, Bettjeman B, Budhidarmo R, Mace PD, Shirley S, Condon SM, Chunduru SK, McKinlay MA, Vaux DL, Silke J, Day CL.

J Biol Chem. 2011 May 13;286(19):17015-28. doi: 10.1074/jbc.M111.222919. Epub 2011 Mar 10.

27.

Molecular cell death platforms and assemblies.

Mace PD, Riedl SJ.

Curr Opin Cell Biol. 2010 Dec;22(6):828-36. doi: 10.1016/j.ceb.2010.08.004. Review.

28.

Activation and specificity of human caspase-10.

Wachmann K, Pop C, van Raam BJ, Drag M, Mace PD, Snipas SJ, Zmasek C, Schwarzenbacher R, Salvesen GS, Riedl SJ.

Biochemistry. 2010 Sep 28;49(38):8307-15. doi: 10.1021/bi100968m.

29.

Asymmetric recruitment of cIAPs by TRAF2.

Mace PD, Smits C, Vaux DL, Silke J, Day CL.

J Mol Biol. 2010 Jul 2;400(1):8-15. doi: 10.1016/j.jmb.2010.04.055. Epub 2010 May 4.

PMID:
20447407
30.

Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding.

Feltham R, Moulin M, Vince JE, Mace PD, Wong WW, Anderton H, Day CL, Vaux DL, Silke J.

J Biol Chem. 2010 Jun 4;285(23):17525-36. doi: 10.1074/jbc.M109.087635. Epub 2010 Mar 30. Erratum in: J Biol Chem. 2017 Aug 25;292(34):14310.

31.

TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis.

Vince JE, Pantaki D, Feltham R, Mace PD, Cordier SM, Schmukle AC, Davidson AJ, Callus BA, Wong WW, Gentle IE, Carter H, Lee EF, Walczak H, Day CL, Vaux DL, Silke J.

J Biol Chem. 2009 Dec 18;284(51):35906-15. doi: 10.1074/jbc.M109.072256.

32.

Assembling the building blocks: structure and function of inhibitor of apoptosis proteins.

Mace PD, Shirley S, Day CL.

Cell Death Differ. 2010 Jan;17(1):46-53. doi: 10.1038/cdd.2009.45. Review.

33.

Structures of the cIAP2 RING domain reveal conformational changes associated with ubiquitin-conjugating enzyme (E2) recruitment.

Mace PD, Linke K, Feltham R, Schumacher FR, Smith CA, Vaux DL, Silke J, Day CL.

J Biol Chem. 2008 Nov 14;283(46):31633-40. doi: 10.1074/jbc.M804753200. Epub 2008 Sep 10.

34.

Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans.

Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL.

Cell Death Differ. 2008 May;15(5):841-8. doi: 10.1038/sj.cdd.4402309. Epub 2008 Jan 25.

35.

High resolution structures of the bone morphogenetic protein type II receptor in two crystal forms: implications for ligand binding.

Mace PD, Cutfield JF, Cutfield SM.

Biochem Biophys Res Commun. 2006 Dec 29;351(4):831-8. Epub 2006 Nov 10.

PMID:
17094948
36.

Bacterial expression and purification of the ovine type II bone morphogenetic protein receptor ectodomain.

Mace PD, Cutfield JF, Cutfield SM.

Protein Expr Purif. 2007 Mar;52(1):40-9. Epub 2006 Aug 12.

PMID:
16982201

Supplemental Content

Support Center